{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T01:05:48Z","timestamp":1778720748128,"version":"3.51.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,6,22]],"date-time":"2018-06-22T00:00:00Z","timestamp":1529625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,6,22]],"date-time":"2018-06-22T00:00:00Z","timestamp":1529625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This study aimed to examine the effectiveness of defibrinogen therapy on functional recovery and safety among 1332 consecutive ischemic stroke patients who had not received intravenous thrombolysis with recombinant tissue plasminogen activator. Stroke patients undergoing conservative and relatively individualized multiple-day dosing regimens of defibrinogen therapy between January 1, 2008 and May 30, 2016 were enrolled. Data were analyzed according to functional success (Barthel Index of 95 or 100, mRS of 0 or 1) and safety variables (intracranial hemorrhage, mortality and stroke recurrence). At 12 months, 18.62% (203\/1087) of patients were lost to follow-up. The functional success rates were 39.84% (526\/1320) and 42.23% (459\/1087) as assessed by BI at 3 months and 12 months, respectively. Fifteen patients had asymptomatic intracranial hemorrhage within 24\u2009hours after the initial defibrase administration. During the 14 days after hospitalization, 12 patients were diagnosed with symptomatic intracranial hemorrhage (sICH) and a total of 12 patients died from all causes. At 3 months, 56 patients were dead and 21 patients had recurrent stroke. The percentage of death and recurrence of stroke at 12 months were 6.81% and 3.22%, respectively. Results from the historical control showed no significant differences of functional success were detected between the patients treated with rt-PA within 6\u2009hours of stroke onset in NINDS II and the patients treated with defibrase within 6\u2009hours after stroke in the present study. The multiple-day dosing regimen of defibrinogen therapy using defibrase applied in the present study could achieve functional improvement among acute ischemic stroke patients, with low risks of mortality when compared with other similar studies. However, the efficacy and safety of such a defibrinogenating therapy is needed to be verified by RCTs with large sample size.<\/jats:p>","DOI":"10.1038\/s41598-018-27856-6","type":"journal-article","created":{"date-parts":[[2018,6,18]],"date-time":"2018-06-18T08:50:30Z","timestamp":1529311830000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Defibrinogen Therapy for Acute Ischemic Stroke: 1332 Consecutive Cases"],"prefix":"10.1038","volume":"8","author":[{"given":"Jing","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dalong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingli","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shufan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuancheng","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,22]]},"reference":[{"key":"27856_CR1","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","volume":"380","author":"R Lozano","year":"2012","unstructured":"Lozano, R. et al. Global and Regional Mortality From 235 Causes of Death for 20 Age Groups in 1990 and 2010: A Systematic Analysis for the Global Burden of Disease Study 2010. LANCET. 380, 2095\u20132128 (2012).","journal-title":"LANCET."},{"key":"27856_CR2","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1002\/ana.20741","volume":"59","author":"VE O\u2019Collins","year":"2006","unstructured":"O\u2019Collins, V. E. et al. 1,026 Experimental Treatments in Acute Stroke. ANN NEUROL. 59, 467\u2013477 (2006).","journal-title":"ANN NEUROL."},{"key":"27856_CR3","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1212\/WNL.0b013e31829bfde3","volume":"81","author":"CF Tsai","year":"2013","unstructured":"Tsai, C. F., Thomas, B. & Sudlow, C. L. Epidemiology of Stroke and its Subtypes in Chinese Vs White Populations: A Systematic Review. NEUROLOGY. 81, 264\u2013272 (2013).","journal-title":"NEUROLOGY."},{"key":"27856_CR4","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1161\/STROKEAHA.113.002504","volume":"45","author":"A Tamm","year":"2014","unstructured":"Tamm, A. et al. Impact of Stroke Care Unit On Patient Outcomes in a Community Hospital. STROKE. 45, 211\u2013216 (2014).","journal-title":"STROKE."},{"key":"27856_CR5","unstructured":"Stroke Unit Trialists\u2019 Collaboration Organised Inpatient (Stroke Unit) Care for Stroke. Cochrane Database Syst Rev. D197 (2013)."},{"key":"27856_CR6","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(14)60584-5","volume":"384","author":"J Emberson","year":"2014","unstructured":"Emberson, J. et al. Effect of Treatment Delay, Age, and Stroke Severity On the Effects of Intravenous Thrombolysis with Alteplase for Acute Ischaemic Stroke: A Meta-Analysis of Individual Patient Data From Randomised Trials. LANCET. 384, 1929\u20131935 (2014).","journal-title":"LANCET."},{"key":"27856_CR7","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1212\/WNL.0000000000002176","volume":"85","author":"CJ Chen","year":"2015","unstructured":"Chen, C. J. et al. Endovascular Vs Medical Management of Acute Ischemic Stroke. NEUROLOGY. 85, 1980\u20131990 (2015).","journal-title":"NEUROLOGY."},{"key":"27856_CR8","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1747-4949.2011.00637.x","volume":"7","author":"B Fuentes","year":"2012","unstructured":"Fuentes, B. et al. Benefits of Intravenous Thrombolysis in Acute Ischemic Stroke Related to Extra Cranial Internal Carotid Dissection. Dream Or Reality? INT J STROKE. 7, 7\u201313 (2012).","journal-title":"INT J STROKE."},{"key":"27856_CR9","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1161\/STROKEAHA.110.609693","volume":"42","author":"CH Riedel","year":"2011","unstructured":"Riedel, C. H. et al. The Importance of Size: Successful Recanalization by Intravenous Thrombolysis in Acute Anterior Stroke Depends On Thrombus Length. STROKE. 42, 1775\u20131777 (2011).","journal-title":"STROKE."},{"key":"27856_CR10","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1177\/1747493015609778","volume":"11","author":"N Wahlgren","year":"2016","unstructured":"Wahlgren, N. et al. Mechanical Thrombectomy in Acute Ischemic Stroke: Consensus Statement by ESO-Karolinska Stroke Update 2014\/2015, Supported by ESO, ESMINT, ESNR and EAN. INT J STROKE. 11, 134\u2013147 (2016).","journal-title":"INT J STROKE."},{"key":"27856_CR11","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/1047-2797(92)90095-8","volume":"2","author":"WB Kannel","year":"1992","unstructured":"Kannel, W. B., D\u2019Agostino, R. B. & Belanger, A. J. Update On Fibrinogen as a Cardiovascular Risk Factor. ANN EPIDEMIOL. 2, 457\u2013466 (1992).","journal-title":"ANN EPIDEMIOL."},{"key":"27856_CR12","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1136\/hrt.69.4.338","volume":"69","author":"AJ Lee","year":"1993","unstructured":"Lee, A. J., Lowe, G. D., Woodward, M. & Tunstall-Pedoe, H. Fibrinogen in Relation to Personal History of Prevalent Hypertension, Diabetes, Stroke, Intermittent Claudication, Coronary Heart Disease, and Family History: The Scottish Heart Health Study. Br Heart J. 69, 338\u2013342 (1993).","journal-title":"Br Heart J."},{"key":"27856_CR13","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1136\/bmj.303.6803.605","volume":"303","author":"N Qizilbash","year":"1991","unstructured":"Qizilbash, N., Jones, L., Warlow, C. & Mann, J. Fibrinogen and Lipid Concentrations as Risk Factors for Transient Ischaemic Attacks and Minor Ischaemic Strokes. BMJ. 303, 605\u2013609 (1991).","journal-title":"BMJ."},{"key":"27856_CR14","doi-asserted-by":"publisher","first-page":"242","DOI":"10.2174\/1567202614666170621103604","volume":"14","author":"S You","year":"2017","unstructured":"You, S. et al. Hyperfibrinogenemia is Significantly Associated with an Increased Risk of In-Hospital Mortality in Acute Ischemic Stroke Patients. CURR NEUROVASC RES. 14, 242\u2013249 (2017).","journal-title":"CURR NEUROVASC RES."},{"key":"27856_CR15","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1161\/STROKEAHA.108.527804","volume":"40","author":"ZG Del","year":"2009","unstructured":"Del, Z. G. et al. Hyperfibrinogenemia and Functional Outcome From Acute Ischemic. Stroke. STROKE. 40, 1687\u20131691 (2009).","journal-title":"Stroke. STROKE."},{"key":"27856_CR16","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jstrokecerebrovasdis.2008.07.009","volume":"18","author":"DE Levy","year":"2009","unstructured":"Levy, D. E., Trammel, J. & Wasiewski, W. W. Ancrod for Acute Ischemic Stroke: A New Dosing Regimen Derived From Analysis of Prior Ancrod Stroke Studies. J Stroke Cerebrovasc Dis. 18, 23\u201327 (2009).","journal-title":"J Stroke Cerebrovasc Dis."},{"key":"27856_CR17","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3233\/BIR-1973-10320","volume":"10","author":"AM Ehrly","year":"1973","unstructured":"Ehrly, A. M. Influence of Arwin On the Flow Properties of Blood. BIORHEOLOGY. 10, 453\u2013456 (1973).","journal-title":"BIORHEOLOGY."},{"key":"27856_CR18","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1001\/archneur.1983.04050120053007","volume":"40","author":"V Hossmann","year":"1983","unstructured":"Hossmann, V., Heiss, W. D., Bewermeyer, H. & Wiedemann, G. Controlled Trial of Ancrod in Ischemic Stroke. Arch Neurol. 40, 803\u2013808 (1983).","journal-title":"Arch Neurol."},{"key":"27856_CR19","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/00000441-199005000-00006","volume":"299","author":"VE Pollak","year":"1990","unstructured":"Pollak, V. E., Glas-Greenwalt, P., Olinger, C. P., Wadhwa, N. K. & Myre, S. A. Ancrod Causes Rapid Thrombolysis in Patients with Acute Stroke. AM J MED SCI. 299, 319\u2013325 (1990).","journal-title":"AM J MED SCI."},{"key":"27856_CR20","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S0140-6736(68)91466-9","volume":"1","author":"AA Sharp","year":"1968","unstructured":"Sharp, A. A., Warren, B. A., Paxton, A. M. & Allington, M. J. Anticoagulant Therapy with a Purified Fraction of Malayan Pit Viper Venom. LANCET. 1, 493\u2013499 (1968).","journal-title":"LANCET."},{"key":"27856_CR21","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/0049-3848(79)90024-0","volume":"14","author":"A Gent","year":"1979","unstructured":"Gent, A., Ingram, G. I., Arocha-Pinango, C. L., Fenton, P. & Buckley, R. J. Central Retinal Vein Thrombosis: Serial Treatment with Defibrination, Aspirin and Plasminotropic Drugs. THROMB RES. 14, 61\u201366 (1979).","journal-title":"THROMB RES."},{"key":"27856_CR22","doi-asserted-by":"publisher","first-page":"431","DOI":"10.3109\/00365517809108447","volume":"38","author":"KH Tonnesen","year":"1978","unstructured":"Tonnesen, K. H., Sager, P. & Gormsen, J. Treatment of Severe Foot Ischaemia by Defibrination with Ancrod: A Randomized Blind Study. Scand J Clin Lab Invest. 38, 431\u2013435 (1978).","journal-title":"Scand J Clin Lab Invest."},{"key":"27856_CR23","doi-asserted-by":"publisher","first-page":"3796","DOI":"10.1161\/STROKEAHA.109.565119","volume":"40","author":"DE Levy","year":"2009","unstructured":"Levy, D. E. et al. Ancrod in Acute Ischemic Stroke: Results of 500 Subjects Beginning Treatment within 6 Hours of Stroke Onset in the Ancrod Stroke Program. STROKE. 40, 3796\u20133803 (2009).","journal-title":"STROKE."},{"key":"27856_CR24","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1016\/S0140-6736(06)69776-6","volume":"368","author":"MG Hennerici","year":"2006","unstructured":"Hennerici, M. G. et al. Intravenous Ancrod for Acute Ischaemic Stroke in the European Stroke Treatment with Ancrod Trial: A Randomised Controlled Trial. LANCET. 368, 1871\u20131878 (2006).","journal-title":"LANCET."},{"key":"27856_CR25","unstructured":"Cooperative Group for Reassessment of Defibrase. Reassessment of Defibrase in Treatment of Acute Cerebral Infarction: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Chin Med Sci J. 20, 151\u2013158 (2005)."},{"key":"27856_CR26","doi-asserted-by":"crossref","unstructured":"Ancrod for the Treatment of Acute Ischemic Brain Infarction. The Ancrod Stroke Study Investigators. Stroke. 25, 1755\u20131759 (1994).","DOI":"10.1161\/01.STR.25.9.1755"},{"key":"27856_CR27","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1001\/jama.283.18.2395","volume":"283","author":"DG Sherman","year":"2000","unstructured":"Sherman, D. G. et al. Intravenous Ancrod for Treatment of Acute Ischemic Stroke: The STAT Study: A Randomized Controlled Trial. Stroke Treatment with Ancrod Trial. JAMA. 283, 2395\u20132403 (2000).","journal-title":"JAMA."},{"key":"27856_CR28","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0196-0644(88)80071-4","volume":"17","author":"CP Olinger","year":"1988","unstructured":"Olinger, C. P. et al. Use of Ancrod in Acute Or Progressing Ischemic Cerebral Infarction. ANN EMERG MED. 17, 1208\u20131209 (1988).","journal-title":"ANN EMERG MED."},{"key":"27856_CR29","unstructured":"The Cooperative Group for Reassessment of Defibrase. Reassessment of Defibrase in Treatment of Cerebral Infarction. Chin Med Sci J. 33, 263\u2013267 (2000)."},{"key":"27856_CR30","doi-asserted-by":"crossref","unstructured":"Hao, Z. et al. Fibrinogen Depleting Agents for Acute Ischaemic Stroke. Cochrane Database Syst Rev. D91 (2012).","DOI":"10.1002\/14651858.CD000091.pub2"},{"key":"27856_CR31","doi-asserted-by":"crossref","unstructured":"Tissue Plasminogen Activator for Acute Ischemic Stroke. N Engl J Med. 333, 1581\u20131587 (1995).","DOI":"10.1056\/NEJM199512143332401"},{"key":"27856_CR32","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1161\/01.STR.0000196957.55928.ab","volume":"37","author":"JL Saver","year":"2006","unstructured":"Saver, J. L. Time is brain-quantified. Stroke 37, 263\u20136 (2006).","journal-title":"Stroke"},{"key":"27856_CR33","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1161\/01.STR.0000258112.14918.24","volume":"38","author":"JH Rha","year":"2007","unstructured":"Rha, J. H. & Saver, J. L. The impact of re-canalization on ischemic stroke outcome: a meta-analysis. Stroke. 38, 967\u201373 (2007).","journal-title":"Stroke."},{"key":"27856_CR34","first-page":"62","volume":"64","author":"J Dutta","year":"2016","unstructured":"Dutta, J. et al. Plasma fibrinogen level in acute stroke - A hospital based study. J Assoc Physicians India. 64, 62\u20133 (2016).","journal-title":"J Assoc Physicians India."},{"key":"27856_CR35","first-page":"88","volume":"9","author":"M Beg","year":"2007","unstructured":"Beg, M. et al. Role of serum fibrinogen in patients of ischemic cerebrovascular disease. Nepal Med Coll J. 9, 88\u201392 (2007).","journal-title":"Nepal Med Coll J."},{"key":"27856_CR36","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s11239-014-1122-1","volume":"38","author":"M Swarowska","year":"2014","unstructured":"Swarowska, M. et al. Hyperfibrinogenemia predicts long-term risk of death after ischemic stroke. J Thromb Thrombolysis 38, 517\u201321 (2014).","journal-title":"J Thromb Thrombolysis"},{"key":"27856_CR37","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/S0950-3536(87)80026-4","volume":"1","author":"GD Lowe","year":"1987","unstructured":"Lowe, G. D. Blood Rheology in General Medicine and Surgery. Baillieres Clin Haematol. 1, 827\u2013861 (1987).","journal-title":"Baillieres Clin Haematol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-27856-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-27856-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-27856-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T06:42:47Z","timestamp":1671604967000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-27856-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,22]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["27856"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-27856-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,22]]},"assertion":[{"value":"21 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"9489"}}